Document Type : Original Article


Faculty of Pharmacy, DIT University, Mussoorie diversion Road, Dehradun-248009, Uttarakhand, India


Epilepsy is a central nervous system disorder (neurological disorder) in which the nerve cell activity in the brain becomes disrupted, causing unprovoked, recurrent seizures or unusual behavior, sensations or even unconsciousness.  In this research work, Pregablin selected as a molecule for designing a emulgel using novel bio-functional agent and compared with standard polymer. This can be overcome by  minimizing the dose and side-effects of API molecule used for various routes. The Pregablin loaded emulgel was prepared using novel bio-functional agent isolated from fruit pulp of Musa acuminata and with standard polymer (sodium alginate) with different ratios. The prepared formulations were evaluated for pH stability studies, % entrapment efficacy, in-vitro drug release and stability studies. The prepared emulgel was subjected to the best formulation based on comparison of above mentioned evaluation parameters, FM2 formulation was found to be the best formulation showing an R2 value of  0.9487, T50%  of 23.52 h and T80%  of 60.22 h respectively. According to the release kinetics, the best fit model was Peppas Korsmeyer with Fickian Diffusion (Higuchi Matrix) as the mechanism of drug release. Musa acuminata provided the excellent stability for the formulation. The results revealed that, uaing Musa acuminata as bio-functional agent was safe and compatible with drug, so Pregablin loaded emulgel can be more affective for brain targeting upon trans-cranial administration.

Graphical Abstract

An innovative approach delivery of anticonvulsant via transcranial route using a smart bio-functional agent cum musa acuminata


[1]. Guzel O. J of Bio Trace Ele Res., 2016, 178:1

[2]. Marra V. Epilepsy Research, 2015, 10:6

[3]. Khambhati A.N., Davis K.A, Oommen B.S, Chen S.H, Lucas T.H, Litt B. PLOS Computational Biology, 2015, 11:1

[4]. Danzer S. Neuron Journal, 2012, 75:739

[5]. Pathirana W., Kariyawasam S.H., Tibbotumunwa H., Perera K. Indian J Pharm Sci., 2006, 68:493

[6]. Pathirana W., Abhayawadhana P., Kariyawasam S.H., Ratnasooriya W.D. Indian J. Pharm Sci., 2009, 71:264

[7]. Kamila S., Madhav  N.V.S., Sarkar C.N. IJPSR., 2015, 6:1000

[8]. Varshney S., Madhav N.V.S. J. Mol. Medi. and Clin App., 2017, 2:1

[9]. Kotecha R.K., Bhadra S., Rajesh K.S. Int J of Phar and Pharmaceut Sci., 2013, 4:490

[10]. Francis D., Mouftah S., Steffen R., Beduneau A., Pellequer Y., Lamprech A. Eur J Pharm Biopharm., 2015, 89:56

[11]. Madhav N.V.S., Yadav A.P. Acta Pharmaceutica Sinica B., 2013, 6:408

[12]. Dattatraya S.M., Loknete J.D. Int. J. Phar. and Pharmaceut Sci., 2018, 10:93